Table 3.
Multivariate survival analysis in 186 “high-grade OC” patients. Analysis in (A) EZH2 high expressing cancers and (B) EZH2 ultra-high expressing cancers.
| Variable | Progression free survival | Overall survival | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| A: EZH2 high expressing cancers | |||||
| Age | Low versus high | 1.74 (1.14–2.66) | 0.010 | 2.40 (1.61–3.58) | < 0.001 |
| FIGO stage | I/II versus III/IV | 2.06 (1.03–4.14) | 0.041 | 1.15 (0.62–2.13) | 0.658 |
| Residual disease | No versus yes | 2.51 (1.56–4.06) | < 0.001 | 2.68 (1.64–4.37) | < 0.001 |
| SMARCA4 (30th percentile) | Low versus high | 0.76 (0.50–1.15) | 0.189 | 0.64 (0.43–0.95) | 0.025 |
| EZH2 (29th percentile) | Low versus high | 1.67 (1.01–2.74) | 0.045 | 1.45 (0.92–2.28) | 0.108 |
| B: EZH2 ultra-high expressing cancers | |||||
| Age | Low versus high | 1.66 (1.09–2.52) | 0.017 | 2.28 (1.54–3.37) | < 0.001 |
| FIGO stage | I/II versus III/IV | 2.50 (1.25–5.00) | 0.010 | 1.32 (0.71–2.45) | 0.378 |
| Residual disease | No versus yes | 2.36 (1.46–3.80) | < 0.001 | 2.46 (1.51–4.01) | < 0.001 |
| SMARCA4 (30th percentile) | Low versus high | 0.95 (0.63–1.44) | 0.819 | 0.74 (0.50–1.09) | 0.124 |
| EZH2 (94th percentile) | Low versus high | 0.20 (0.06–0.65) | 0.007 | 0.43 (0.17–1.07) | 0.069 |
HR hazard ratio.
Bold values indicate P < 0.05. The significance level was determined by Cox regression analysis.